BioSpectrum ASIA EDITION
the business of Bio & Health Sciences

Myriad Genetics expands SRL partnership in Japan to support future growth

November 18, 2026 | News

Enhanced partnership expected to strengthen Myriad's position in its largest international market



Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, has announced an expansion of its collaboration with SRL, one of the Japan's largest and leading clinical laboratory testing companies, to enable local testing for BRACAnalysis® Diagnostic System in Japan, subject to regulatory approval.

The collaboration is expected to improve the testing experience for patients and health care providers, while creating a foundation for broader Myriad offerings and long-term growth in Japan.

Under the expanded agreement, SRL will perform all laboratory wet work for BRACAnalysis Diagnostic System locally in Japan, while Myriad will continue to provide genetic interpretation services. Because this approach eliminates the need to ship patient samples to Myriad’s central laboratory in Utah for sequencing, it is expected to improve testing efficiency and shorten sample turn-around-time for the clinician and the patient.

The expanded collaboration is also expected to establish local capabilities that could support additional precision medicine and companion diagnostic offerings in the future. In partnership with SRL, Myriad intends to pursue additional regulatory approvals and reimbursement to strengthen the company’s ability to serve the Japanese healthcare system.